|
注册号: Registration number: |
ChiCTR2000040308 |
|
最近更新日期: Date of Last Refreshed on: |
2021-02-14 06:31:12 |
|
注册时间: Date of Registration: |
2020-11-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
血管老化表型在老年人群中的心血管疾病预测和干预价值 |
|
Public title: |
The value of vascular aging phenotype in cardiovascular disease prediction and intervention in the elderly population |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
血管老化表型在老年人群中的心血管疾病预测和干预价值 |
|
Scientific title: |
The value of vascular aging phenotype in cardiovascular disease prediction and intervention in the elderly population |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
白娅娅 |
研究负责人: |
左君丽 |
|
Applicant: |
Bai Yaya |
Study leader: |
Zuo Junli |
|
申请注册联系人电话: Applicant telephone: |
+86 17317818942 |
研究负责人电话:
Study leader's |
+86 18121263127 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
823946631@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
zuo-junli@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市嘉定区希望路999号住院部9楼B区 |
研究负责人通讯地址: |
上海市嘉定区希望路999号住院部9楼B区 |
|
Applicant address: |
999 Xiwang Road, Jiading District, Shanghai, China |
Study leader's address: |
999 Xiwang Road, Jiading District, Shanghai, China |
|
申请注册联系人邮政编码: Applicant postcode: |
201800 |
研究负责人邮政编码: Study leader's postcode: |
201800 |
|
申请人所在单位: |
上海交通大学医学院附属瑞金医院(北部院区) |
||
|
Applicant's institution: |
Department of Geriatrics, Ruijin Hospital North, Shanghai Jiaotong University School of Medicine |
||
|
研究负责人所在单位: |
上海交通大学医学院附属瑞金医院(北部院区) |
||
|
Affiliation of the Leader: |
Department of Geriatrics, Ruijin Hospital North, Shanghai Jiaotong University School of Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2011-30 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市徐汇区中心医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Shanghai Xuhui District Central Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2011-09-08 00:00:00 | ||
|
伦理委员会联系人: |
王燕燕 |
||
|
Contact Name of the ethic committee: |
Wang Yanyan |
||
|
伦理委员会联系地址: |
上海市淮海中路966号(200031) |
||
|
Contact Address of the ethic committee: |
966 Huaihai Road, Shanghai 200031,China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
上海交通大学医学院附属瑞金医院(北部院区) |
||||||||||||||||||||||
|
Primary sponsor: |
Department of Geriatrics, Ruijin Hospital North, Shanghai Jiaotong University School of Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市嘉定区希望路999号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
999 Xiwang Road, Jiading District, Shanghai, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海市卫生健康委员会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai Health Commission |
||||||||||||||||||||||
|
研究疾病: |
高血压血管老化 |
||||||||||||||||||||||
|
Target disease: |
Vascular Aging in Hypertension |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
①本研究将分析健康及合并慢病老年人群的血管老化指标(c-fPWV及其他组织生物标志物),获取中国人群的PWV参考值和正常值。 ②通过探索早期血管衰老人群的危险因素,尤其超正常血管老化人群(SUPERNOVA)的保护性因素,形成老年血管疾病的预防及诊疗规范,从而延缓早期血管老化的发生发展。 ③通过前瞻性随访研究,明确不同血管衰老分型与心血管靶器官损害及心血管事件风险的关联性、不同循环生物标志物指标与c-fPWV等意义明确血管衰老预测指标的相关性,识别危险因素和治疗策略的干预有效性。 ④通过本研究的数据,建立早期血管老化风险识别的关键技术,通过早期识别危险人群,干预并保护血管功能,从而降低心血管事件终点风险,促进老年人身心健康,提高生活质量。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study will analyze the vascular aging index (cf-PWV and other tissue biomarkers) of healthy and elderly people with chronic diseases, and obtain the PWV reference value and normal value of Chinese population. By exploring the risk factors of early vascular aging population, especially the protective factors of supernormal vascular aging population (SUPERNOVA), the prevention, diagnosis and treatment of elderly vascular diseases are formed, thus delaying the occurrence and development of early vascular aging. By prospective follow-up study, the correlation between different types of vascular senescence and cardiovascular target organ damage and cardiovascular event risk, different circulating biomarker index and cf-PWV were identified. Through the data of this study, the key technology of early vascular aging risk identification is established, and the risk of cardiovascular events is reduced, the physical and mental health of the elderly is promoted and the quality of life is improved. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
排除标准 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Cerebrovascular events occurred within the first three months; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-12-25 00:00:00至 To 2023-08-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-12-25 00:00:00 至 To 2023-08-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
No |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
N/A |
|
Blinding: |
N/A |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
Not stated |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Not stated |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
Not stated |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Not stated |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |